Lots of Good News out for Otonomy Inc (NASDAQ:OTIC)

Otonomy Inc (NASDAQ:OTIC)

Otonomy Inc (NASDAQ:OTIC)

Otonomy Inc (NASDAQ:OTIC) released their Q3 earnings after today’s market close and beat analyst expectations. Otonomy posted a net loss of (-$20.99) million, or (-$0.69) per share – versus the consensus forecast of a (-$0.76) EPS loss. Revenues for the quarter came in at $300,000.

Otonomy Inc (NASDAQ:OTIC)

San Diego, CA-based Otonomy Inc (NASDAQ:OTIC) is a biopharmaceutical company that develops and commercializes therapeutics for patients suffering from ear diseases and disorders. FDA-approved OTIPRIO® (ciprofloxacin otic suspension) is used during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has been completed with the FDA for acute otitis media with tympanostomy tubes (AOMT). OTIVIDEXTM is a steroid in development for the treatment of Ménière’s disease.

David A. Weber, Ph.D., president and CEO of Otonomy Inc (NASDAQ:OTIC) said “Today’s announcement of successful results for OTIVIDEX in the AVERTS-2 trial is an important milestone for the company and renews our excitement and commitment to continuing the registration program for OTIVIDEX in Ménière’s disease. We believe that the continuation of OTIVIDEX development for Ménière’s disease and the advancement of our other programs targeting important unmet medical needs including hearing loss and tinnitus provide an attractive path forward for Otonomy.”

Phase 3 Endpoints Met

Otonomy Inc (NASDAQ:OTIC) also announced today that the AVERTS-2 Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease achieved its primary efficacy endpoint. The OTIVIDEX group demonstrated a 6.2 day reduction in the mean reported number of DVD from baseline to Month 3 with a 2.5 day mean difference between OTIVIDEX and placebo in Month 3. Otonomy plans to review these results with the U.S. Food and Drug Administration (FDA) and discuss clinical requirements for registration of OTIVIDEX for patients with Ménière’s disease. The company expects to provide an update from discussions with the FDA during the first quarter of 2018.

OTIC Stock Performance

Otonomy Inc (NASDAQ:OTIC) sales were first reported in 2016. That figure was $700,000. Earnings for 2016 were, on a per share basis, reported as a loss of (-$3.69). For the year prior, 2015, the EPS loss was (-$2.58).

The current closing price of $2.80 represents a large discount to the stock’s cash/share value of $4.97 as well as its book/share value of $4.96.

Four investment firms follow Otonomy Inc (NASDAQ:OTIC). Two rate OTIC stock as a “Strong Buy”, while the other two rate the shares as a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OTIC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *